PL4054584T3 - Sposoby leczenia i/albo zapobiegania poważnym niepożądanym zdarzeniom sercowo- naczyniowym (MACE) z wykorzystaniem kombinacji inhibitora bromodomeny BET i zależnego od sodu inhibitora transportera glukozy typu 2 - Google Patents
Sposoby leczenia i/albo zapobiegania poważnym niepożądanym zdarzeniom sercowo- naczyniowym (MACE) z wykorzystaniem kombinacji inhibitora bromodomeny BET i zależnego od sodu inhibitora transportera glukozy typu 2Info
- Publication number
- PL4054584T3 PL4054584T3 PL20884269.0T PL20884269T PL4054584T3 PL 4054584 T3 PL4054584 T3 PL 4054584T3 PL 20884269 T PL20884269 T PL 20884269T PL 4054584 T3 PL4054584 T3 PL 4054584T3
- Authority
- PL
- Poland
- Prior art keywords
- inhibitor
- mace
- prevention
- treatment
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962930860P | 2019-11-05 | 2019-11-05 | |
| PCT/IB2020/000912 WO2021090061A1 (en) | 2019-11-05 | 2020-11-04 | Methods of treatment and/or prevention of major adverse cardiovascular events (mace) with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4054584T3 true PL4054584T3 (pl) | 2025-11-03 |
Family
ID=75849803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20884269.0T PL4054584T3 (pl) | 2019-11-05 | 2020-11-04 | Sposoby leczenia i/albo zapobiegania poważnym niepożądanym zdarzeniom sercowo- naczyniowym (MACE) z wykorzystaniem kombinacji inhibitora bromodomeny BET i zależnego od sodu inhibitora transportera glukozy typu 2 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US12551484B2 (pl) |
| EP (1) | EP4054584B1 (pl) |
| JP (1) | JP7502811B2 (pl) |
| KR (1) | KR102935008B1 (pl) |
| CN (1) | CN114650824A (pl) |
| AU (1) | AU2020377539B2 (pl) |
| BR (1) | BR112022008223A2 (pl) |
| CA (1) | CA3160147A1 (pl) |
| DK (1) | DK4054584T3 (pl) |
| ES (1) | ES3042146T3 (pl) |
| FI (1) | FI4054584T3 (pl) |
| HU (1) | HUE073043T2 (pl) |
| IL (1) | IL292696B2 (pl) |
| MX (1) | MX2022005029A (pl) |
| PL (1) | PL4054584T3 (pl) |
| PT (1) | PT4054584T (pl) |
| TW (1) | TWI867086B (pl) |
| WO (1) | WO2021090061A1 (pl) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI867086B (zh) | 2019-11-05 | 2024-12-21 | 加拿大商瑞斯弗洛吉克斯公司 | 以rvx-208及sglt2抑制劑治療及/或預防主要不良心血管事件(mace)的方法 |
| WO2022091029A1 (en) * | 2020-10-30 | 2022-05-05 | Resverlogix Corp. | Methods for lowering hba1c level with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor |
| WO2022155303A1 (en) * | 2021-01-14 | 2022-07-21 | Lexicon Pharmaceuticals, Inc. | Sotagliflozin for treating or preventing cardiovascular diseases |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5368792B2 (ja) | 2005-07-29 | 2013-12-18 | レスバーロジックス コーポレイション | 複合疾患の予防および処置のための薬学的組成物および挿入可能な医療用デバイスによるその送達 |
| DK2118074T3 (en) | 2007-02-01 | 2014-03-10 | Resverlogix Corp | Compounds for the prevention and treatment of cardiovascular diseases |
| KR101629356B1 (ko) | 2008-06-26 | 2016-06-13 | 리스버로직스 코퍼레이션 | 퀴나졸리논 유도체의 제조방법 |
| KR101709492B1 (ko) | 2009-03-18 | 2017-02-23 | 리스버로직스 코퍼레이션 | 신규한 소염제 |
| SG174504A1 (en) | 2009-03-27 | 2011-10-28 | Bristol Myers Squibb Co | Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors |
| US9757368B2 (en) | 2009-04-22 | 2017-09-12 | Resverlogix Corp. | Anti-inflammatory agents |
| EP2435033A1 (en) | 2009-05-27 | 2012-04-04 | Bristol-Myers Squibb Company | Methods for treating type 2 diabetes in patients resistant to previous treatment with other anti-diabetic drugs employing an sglt2 inhibitor and compositions thereof |
| RU2640115C2 (ru) | 2011-11-01 | 2017-12-26 | Ресверлоджикс Корп. | Фармацевтические композиции замещенных хиназолинонов |
| US20130281398A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| WO2014080291A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Biaryl derivatives as bromodomain inhibitors |
| KR102309654B1 (ko) | 2013-04-18 | 2021-10-08 | 베링거 인겔하임 인터내셔날 게엠베하 | 약제학적 조성물, 치료 방법 및 이의 용도 |
| JP2016528275A (ja) | 2013-08-21 | 2016-09-15 | レスバーロジックス コーポレイション | プラーク退縮を促進するための組成物及び治療法 |
| US20160346291A1 (en) * | 2013-08-21 | 2016-12-01 | Resverlogix Corp | Compositions and therapeutic methods for accelerated plaque regression |
| TW201625605A (zh) * | 2014-04-04 | 2016-07-16 | 賽諾菲公司 | 用於治療糖尿病、肥胖、血脂異常及相關病症之作為ｇｐｒ１１９調節劑的經取代之稠合雜環類 |
| US10111885B2 (en) | 2015-03-13 | 2018-10-30 | Resverlogix Corp. | Compositions and therapeutic methods for the treatment of complement-associated diseases |
| EP3355922A2 (en) * | 2015-10-02 | 2018-08-08 | Dana Farber Cancer Institute, Inc. | Combination therapy of bromodomain inhibitors and checkpoint blockade |
| EP3553058A1 (en) | 2016-12-09 | 2019-10-16 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystal form of bromodomain protein inhibitor drug, preparation method and use thereof |
| US11419883B2 (en) | 2017-05-05 | 2022-08-23 | The Regents Of The University Of California | Inhibiting senescent processes in beta cells for the prevention of type 1 diabetes |
| TWI867086B (zh) | 2019-11-05 | 2024-12-21 | 加拿大商瑞斯弗洛吉克斯公司 | 以rvx-208及sglt2抑制劑治療及/或預防主要不良心血管事件(mace)的方法 |
| US20230241064A1 (en) | 2020-01-08 | 2023-08-03 | Resverlogix Corp. | Methods of treatment and/or prevention of major adverse cardiovascular events (mace) with a combination of a bet bromodomain inhibitor and a dipeptidyl peptidase 4 inhibitor |
| WO2022091029A1 (en) * | 2020-10-30 | 2022-05-05 | Resverlogix Corp. | Methods for lowering hba1c level with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor |
| IL301831A (en) | 2020-10-30 | 2023-06-01 | Resverlogix Corp | Methods for improving renal function with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor |
-
2020
- 2020-11-04 TW TW109138504A patent/TWI867086B/zh active
- 2020-11-04 PL PL20884269.0T patent/PL4054584T3/pl unknown
- 2020-11-04 PT PT208842690T patent/PT4054584T/pt unknown
- 2020-11-04 WO PCT/IB2020/000912 patent/WO2021090061A1/en not_active Ceased
- 2020-11-04 DK DK20884269.0T patent/DK4054584T3/da active
- 2020-11-04 HU HUE20884269A patent/HUE073043T2/hu unknown
- 2020-11-04 MX MX2022005029A patent/MX2022005029A/es unknown
- 2020-11-04 CN CN202080076646.1A patent/CN114650824A/zh active Pending
- 2020-11-04 AU AU2020377539A patent/AU2020377539B2/en active Active
- 2020-11-04 KR KR1020227019038A patent/KR102935008B1/ko active Active
- 2020-11-04 CA CA3160147A patent/CA3160147A1/en active Pending
- 2020-11-04 BR BR112022008223A patent/BR112022008223A2/pt unknown
- 2020-11-04 FI FIEP20884269.0T patent/FI4054584T3/fi active
- 2020-11-04 IL IL292696A patent/IL292696B2/en unknown
- 2020-11-04 JP JP2022525779A patent/JP7502811B2/ja active Active
- 2020-11-04 US US17/774,657 patent/US12551484B2/en active Active
- 2020-11-04 EP EP20884269.0A patent/EP4054584B1/en active Active
- 2020-11-04 ES ES20884269T patent/ES3042146T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP4054584A4 (en) | 2023-11-08 |
| ES3042146T3 (en) | 2025-11-18 |
| US20220370452A1 (en) | 2022-11-24 |
| CN114650824A (zh) | 2022-06-21 |
| IL292696A (en) | 2022-07-01 |
| HUE073043T2 (hu) | 2025-12-28 |
| PT4054584T (pt) | 2025-07-16 |
| EP4054584A1 (en) | 2022-09-14 |
| AU2020377539A1 (en) | 2022-05-19 |
| IL292696B1 (en) | 2026-01-01 |
| KR102935008B1 (ko) | 2026-03-09 |
| KR20220098757A (ko) | 2022-07-12 |
| TWI867086B (zh) | 2024-12-21 |
| JP2023500685A (ja) | 2023-01-10 |
| IL292696B2 (en) | 2026-05-01 |
| JP7502811B2 (ja) | 2024-06-19 |
| US12551484B2 (en) | 2026-02-17 |
| BR112022008223A2 (pt) | 2022-09-06 |
| CA3160147A1 (en) | 2021-05-14 |
| MX2022005029A (es) | 2022-07-12 |
| TW202131924A (zh) | 2021-09-01 |
| AU2020377539B2 (en) | 2025-05-29 |
| DK4054584T3 (en) | 2025-09-01 |
| FI4054584T3 (fi) | 2025-08-22 |
| EP4054584B1 (en) | 2025-07-09 |
| WO2021090061A1 (en) | 2021-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK4054584T3 (en) | Methods of treatment and/or prevention of major adverse cardiovascular events (MACE) with a combination of a BET bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor | |
| SG11202105158VA (en) | Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| IL283598A (en) | Combined treatment with radio-immune conjugates and a checkpoint inhibitor | |
| IL320829A (en) | PARP1 inhibitors and their uses | |
| IL280591A (en) | Methods for delaying the onset of new type 2 diabetes and slowing the progression and treatment of type 2 diabetes | |
| PL4094763T3 (pl) | Związek do stosowania w zapobieganiu i/lub leczeniu stanu wywołanego lub związanego z koronawirusem | |
| GB202204420D0 (en) | Crypto-erasure via internal and/or external action | |
| IL275925A (en) | Prevention and treatment of organ damage | |
| ZA202202617B (en) | Treatment of cancer using a combination comprising multi-tyrosine kinase inhibitor and immune checkpoint inhibitor | |
| EP3995480A4 (en) | AKR1C3 INHIBITOR AND MEDICAL USE | |
| IL294344B1 (en) | Methods for treating and/or preventing major cardiovascular events (MACE) with a combination of a BET bromodomain inhibitor and a dipeptidyl peptidase 4 inhibitor | |
| IL309243A (en) | Radioimmunoconjugates and combination therapy with barrier surveillance | |
| GB202103578D0 (en) | Prevention and treatment of infections including those caused by coronavirus | |
| PL4069278T3 (pl) | Sposoby i kompozycje do zapobiegania cukrzycy typu 1 | |
| HK40076178A (en) | Methods of treatment and/or prevention of major adverse cardiovascular events (mace) with a combination of a bet bromodomain inhibitor and a dipeptidyl peptidase 4 inhibitor | |
| EP4178359A4 (en) | COMBINATION THERAPIES FOR THE TREATMENT AND PREVENTION OF BIOFILMS | |
| HUE059233T2 (hu) | Vegyület epizootius nyúl-enteropátia kezelésében és/vagy megelõzésében való alkalmazásra | |
| PL4061399T3 (pl) | Działanie insulinotropowe i glukagonotropowe beta-laktoglobuliny | |
| IL321017A (en) | Inhibitors and/or decomposers containing 3-fluoro-4-hydroxybenzmide and uses thereof | |
| GB202218617D0 (en) | Triggered-producer and triggered-consumer instructions | |
| GB202210704D0 (en) | Biofilm prevention and treatment | |
| AU2025203707A1 (en) | Methods of inhibiting MASP-2 for the treatment and/or prevention of coronavirus-induced acute respiratory distress syndrome | |
| HK40087806A (en) | Combination therapies for the treatment and prevention of biofilms | |
| CA3278912A1 (en) | Raf inhibitor and kras g12c inhibitor combination therapy | |
| GB202114665D0 (en) | Addition and subtraction board |